389 related articles for article (PubMed ID: 32151779)
1. Intergenic Breakpoints Identified by DNA Sequencing Confound Targetable Kinase Fusion Detection in NSCLC.
Li W; Liu Y; Li W; Chen L; Ying J
J Thorac Oncol; 2020 Jul; 15(7):1223-1231. PubMed ID: 32151779
[TBL] [Abstract][Full Text] [Related]
2. Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer.
Li W; Wan R; Guo L; Chang G; Jiang D; Meng L; Ying J
BMC Med; 2022 May; 20(1):160. PubMed ID: 35534835
[TBL] [Abstract][Full Text] [Related]
3. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
[TBL] [Abstract][Full Text] [Related]
4. Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers.
Xia P; Zhang L; Li P; Liu E; Li W; Zhang J; Li H; Su X; Jiang G
J Transl Med; 2021 Jul; 19(1):308. PubMed ID: 34271921
[TBL] [Abstract][Full Text] [Related]
5. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization.
Diks J; Tang Z; Altan M; Anderson S; Chen H; Rashid A; Yang RK; Routbort MJ; Patel KP; Toruner GA; Medeiros LJ; Tang G; Luthra R; Roy-Chowdhuri S
Cancer Cytopathol; 2024 Jan; 132(1):41-49. PubMed ID: 37747438
[TBL] [Abstract][Full Text] [Related]
6. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M
BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405
[TBL] [Abstract][Full Text] [Related]
7. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
[TBL] [Abstract][Full Text] [Related]
8. An intergenic region ALK fusion identified by DNA sequencing and validated by IHC in an early-stage lung adenocarcinoma.
Dou Y; Duan Q; Qi C; Hou L; Wang H
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1865-1867. PubMed ID: 33544200
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
[TBL] [Abstract][Full Text] [Related]
10. Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC.
Kuang Y; Xu P; Wang J; Zheng Y; Sun X; Li Z; Gan R; Li H; Guo Y; Yao F; Zhu C; Ke Z; Tang K
Mol Diagn Ther; 2021 Jul; 25(4):487-494. PubMed ID: 34133003
[TBL] [Abstract][Full Text] [Related]
11. RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer.
Radonic T; Geurts-Giele WRR; Samsom KG; Roemen GMJM; von der Thüsen JH; Thunnissen E; Meijssen IC; Sleddens HFBM; Dinjens WNM; Boelens MC; Weijers K; Speel EJM; Finn SP; O'Brien C; van Wezel T; Cohen D; Monkhorst K; Roepman P; Dubbink HJ
J Thorac Oncol; 2021 May; 16(5):798-806. PubMed ID: 33588111
[TBL] [Abstract][Full Text] [Related]
12. Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer.
Ding Y; Sun C; Su W; Miao C; He X; Wang JS; Zhang ZH
Virchows Arch; 2022 Sep; 481(3):405-419. PubMed ID: 35624360
[TBL] [Abstract][Full Text] [Related]
13. External Validation of
Kim SW; DO SI; Na K
Anticancer Res; 2021 Sep; 41(9):4609-4617. PubMed ID: 34475089
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of genomic breakpoints of ALK rearrangements in non-small cell lung cancer.
Wang Z; Han Y; Tao H; Xu M; Liu Z; Zhu J; Li W; Ma J; Liu Z; Wang W; Ma T
Mol Oncol; 2023 May; 17(5):765-778. PubMed ID: 36423218
[TBL] [Abstract][Full Text] [Related]
15. Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma.
Brisudova A; Skarda J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Jun; 164(2):127-132. PubMed ID: 32284620
[TBL] [Abstract][Full Text] [Related]
16. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
McLeer-Florin A; Duruisseaux M; Pinsolle J; Dubourd S; Mondet J; Phillips Houlbracq M; Magnat N; Fauré J; Chatagnon A; de Fraipont F; Giaj Levra M; Toffart AC; Ferretti G; Hainaut P; Brambilla E; Moro-Sibilot D; Lantuejoul S
Lung Cancer; 2018 Feb; 116():15-24. PubMed ID: 29413046
[TBL] [Abstract][Full Text] [Related]
17. Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.
Xia H; Liang B; Liu G; Qi Y; Luo N; Li M
Medicine (Baltimore); 2022 Apr; 101(14):e29134. PubMed ID: 35446297
[TBL] [Abstract][Full Text] [Related]
18. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.
Vendrell JA; Taviaux S; Béganton B; Godreuil S; Audran P; Grand D; Clermont E; Serre I; Szablewski V; Coopman P; Mazières J; Costes V; Pujol JL; Brousset P; Rouquette I; Solassol J
Sci Rep; 2017 Oct; 7(1):12510. PubMed ID: 28970558
[TBL] [Abstract][Full Text] [Related]
19. Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
Smuk G; Pajor G; Szuhai K; Morreau H; Kocsmár I; Kocsmár É; Pajor L; Kajtár B; Sárosi V; Lotz G; Tornóczky T
Lung Cancer; 2020 May; 143():80-85. PubMed ID: 32272316
[TBL] [Abstract][Full Text] [Related]
20. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.
Rosenbaum JN; Bloom R; Forys JT; Hiken J; Armstrong JR; Branson J; McNulty S; Velu PD; Pepin K; Abel H; Cottrell CE; Pfeifer JD; Kulkarni S; Govindan R; Konnick EQ; Lockwood CM; Duncavage EJ
Mod Pathol; 2018 May; 31(5):791-808. PubMed ID: 29327716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]